Johannes Oldenburg
Experimental Haematology and Transfusion Medicine, University Clinic Bonn · University Clinic, Bonn · Universitaetsklinikum Bonn
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Johannes Oldenburg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:47 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05936580 · Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma · recruiting · Hemophilia A · principal investigator
- N/ANCT02502409 · Natural History Study of Factor IX Treatment and ComplicationsSkane University Hospital · unknown · Factor IX Deficiency · principal investigator
- Ph3NCT01125813 · Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia AOctapharma · completed · Severe Hemophilia A · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:47 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors.N Engl J Med · 2017913 citationsRCR 38.0
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.N Engl J Med · 2018636 citationsRCR 28.7
- 470 citationsRCR 39.6
- Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.N Engl J Med · 2023459 citationsRCR 38.4
- 330 citationsRCR 20.8
- 255 citationsRCR 19.5
- Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.N Engl J Med · 2023185 citationsRCR 26.8
- 183 citationsRCR 7.0
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.N Engl J Med · 2023182 citationsRCR 18.0
- Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.Blood · 2006177 citationsRCR 4.5